Mr. Agarwal was recognized for contributing to the IQ MPS affiliate group in 2022 and received the CEO Stock Award in 2021 from Alnylam Pharmaceuticals for high performance.
STONEHAM, MA, August 21, 2023 /24-7PressRelease/ -- Saket Agarwal has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Drawing on his considerable experience in biological sciences, Mr. Agarwal presently excels as a Senior Scientist with Alnylam Pharmaceuticals, as a member of the Investigative Toxicology group. As a researcher, he works on optimizing siRNA, or small interfering RNA, safety through improved mechanistic understanding at a cellular and molecular level. Since starting at Alnylam Pharmaceuticals in 2017, he has since been promoted multiple times and expanded his responsibilities considerably leading to up to his current role. Prior to working on RNAi therapeutics, Mr. Agarwal gained valuable experience in developing small molecule drugs and held research positions with Pfizer, Progenra, Inc., Piramal Lifesciences Limited, GlaxoSmithKline, and Merck.
Through Alnylam, Mr. Agarwal co-chaired SAGA, an Employee Resource Group, that is focused on being a source of networking, connection, and support for LGBTQ+ members and is a Steering Committee member of the Innovation and Quality in Microphysiological Systems (IQ MPS) Consortium, which aims to lessen animal usage and predict activity safety pharmacology using complex in-vitro models. An expert in his field, he holds a Bachelor of Science and Master of Science in biological science from Drexel University. In light of his professional achievements, Mr. Agarwal was recognized for contributing to the IQ MPS affiliate group in 2022 and received the CEO Stock Award in 2021 from Alnylam Pharmaceuticals for high performance. Mr. Agarwal has also received several Stellar Supernova Awards from Alnylam Pharmaceuticals for his contribution to Diversity, Equity, and Inclusion initiatives.
While his career has been filled with highlights, Mr. Agarwal takes the most pride in contributing to the understanding of plasma protein binding properties of GalNAc-siRNAs (Agarwal et al., 2021) and helping expand RNAi therapeutics to extrahepatic tissues (Brown, Nair et al., 2022). The cornerstone of his success lies in embracing opportunities outside of his comfort zone. Looking ahead, Mr. Agarwal intends to continue growing in his career and aims to be known as an expert in his field.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Marquis celebrates its 125th anniversary in 2023, and Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® publications may be visited at the official Marquis Who's Who® website at www.marquiswhoswho.com.
# # #